IGF2R

Summary

IGF2R (insulin like growth factor 2 receptor, HGNC:5467) is a protein-coding gene on chromosome 6q25.3, encoding Cation-independent mannose-6-phosphate receptor (P11717). Mediates the transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes.

This gene encodes a receptor for both insulin-like growth factor 2 and mannose 6-phosphate. The binding sites for each ligand are located on different segments of the protein. This receptor has various functions, including in the intracellular trafficking of lysosomal enzymes, the activation of transforming growth factor beta, and the degradation of insulin-like growth factor 2. Mutation or loss of heterozygosity of this gene has been association with risk of hepatocellular carcinoma. The orthologous mouse gene is imprinted and shows exclusive expression from the maternal allele; however, imprinting of the human gene may be polymorphic, as only a minority of individuals showed biased expression from the maternal allele (PMID:8267611).

Source: NCBI Gene 3482 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 395 total — 2 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 4
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_000876

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5467
Approved symbol	IGF2R
Name	insulin like growth factor 2 receptor
Location	6q25.3
Locus type	gene with protein product
Status	Approved
Aliases	CD222, MPRI, MPR1, CIMPR, M6P-R, CI-M6PR, CI-MPR, MPR300
Ensembl gene	ENSG00000197081
Ensembl biotype	protein_coding
OMIM	147280
Entrez	3482

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 retained_intron, 3 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000356956, ENST00000475584, ENST00000475834, ENST00000487607, ENST00000569097, ENST00000649737, ENST00000650503, ENST00000676781, ENST00000677628, ENST00000677704, ENST00000678224

RefSeq mRNA: 1 — MANE Select: NM_000876 NM_000876

CCDS: CCDS5273

Canonical transcript exons

ENST00000356956 — 48 exons

Exon	Start	End
ENSE00001086758	160096439	160096625
ENSE00001086759	160045745	160045882
ENSE00001086760	160010687	160010785
ENSE00001086761	160009010	160009134
ENSE00001086762	160071910	160072036
ENSE00001086764	160048375	160048543
ENSE00001086767	160064804	160064901
ENSE00001086768	160027185	160027314
ENSE00001086769	160024572	160024704
ENSE00001086771	160047792	160047907
ENSE00001086772	160043148	160043288
ENSE00001086773	160073213	160073469
ENSE00001086774	160044514	160044657
ENSE00001086779	159991184	159991323
ENSE00001086780	160061753	160061928
ENSE00001086781	160050473	160050652
ENSE00001086782	160075847	160075996
ENSE00001086784	160034419	160034522
ENSE00001086785	160073757	160073975
ENSE00001086788	160058906	160059098
ENSE00001086789	160060547	160060717
ENSE00001086790	160040560	160040724
ENSE00001086791	160032551	160032713
ENSE00001086793	160068249	160068385
ENSE00001086796	160062532	160062619
ENSE00001086798	160029550	160029655
ENSE00001086799	160063415	160063630
ENSE00001086846	160069868	160070058
ENSE00001086847	160079580	160079787
ENSE00001086848	160064401	160064531
ENSE00001086849	160032942	160033107
ENSE00001086850	160056424	160056525
ENSE00001086853	160072765	160072884
ENSE00001086855	160083950	160084184
ENSE00001086857	160089916	160090103
ENSE00001086858	160084995	160085131
ENSE00001086859	160080129	160080275
ENSE00001086860	160058023	160058124
ENSE00001086861	160061503	160061646
ENSE00001086863	160078201	160078362
ENSE00001375794	159969082	159969395
ENSE00003522053	160088033	160088147
ENSE00003522992	160046498	160046645
ENSE00003553399	160102519	160102671
ENSE00003594053	160047159	160047336
ENSE00003604815	160103746	160103815
ENSE00003681685	160089107	160089253
ENSE00003690118	160104674	160111504

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 98.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 75.6349 / max 2434.8181, expressed in 1819 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
71003	70.9551	1817
71002	3.8772	1578
204277	0.8026	546

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.02	gold quality
gastrocnemius	UBERON:0001388	97.11	gold quality
granulocyte	CL:0000094	97.08	gold quality
adrenal tissue	UBERON:0018303	96.65	gold quality
muscle of leg	UBERON:0001383	96.64	gold quality
blood	UBERON:0000178	96.13	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.99	gold quality
tibialis anterior	UBERON:0001385	95.34	gold quality
leukocyte	CL:0000738	95.31	gold quality
muscle organ	UBERON:0001630	95.24	gold quality
monocyte	CL:0000576	95.09	gold quality
mononuclear cell	CL:0000842	95.06	gold quality
spleen	UBERON:0002106	94.74	gold quality
upper lobe of left lung	UBERON:0008952	94.62	gold quality
upper lobe of lung	UBERON:0008948	94.60	gold quality
right adrenal gland cortex	UBERON:0035827	94.49	gold quality
right lung	UBERON:0002167	94.45	gold quality
left adrenal gland	UBERON:0001234	94.36	gold quality
islet of Langerhans	UBERON:0000006	94.33	gold quality
left adrenal gland cortex	UBERON:0035825	94.27	gold quality
right lobe of liver	UBERON:0001114	94.16	gold quality
heart left ventricle	UBERON:0002084	94.08	gold quality
adrenal gland	UBERON:0002369	94.08	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.02	gold quality
adrenal cortex	UBERON:0001235	94.01	gold quality
left ventricle myocardium	UBERON:0006566	93.99	gold quality
cardiac ventricle	UBERON:0002082	93.97	gold quality
right adrenal gland	UBERON:0001233	93.94	gold quality
omental fat pad	UBERON:0010414	93.87	gold quality
peritoneum	UBERON:0002358	93.83	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	19.76
E-ANND-3	yes	12.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IFNG, MYC, USF1, USF2

miRNA regulators (miRDB)

238 targeting IGF2R, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-6077	99.99	68.04	2299

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• SNPs in American and Japanese populations (PMID:11438990)
• Contribution of residues A54 and L55 of the human insulin-like growth factor-II (IGF-II) A domain to Type 2 IGF receptor binding specificity (PMID:11811790)
• The 1.4 A resolution crystal structure of domain 11 was solved using the anomalous scattering signal of sulfur. It consists of two crossed beta-sheets forming a flattened beta-barrel with a putative IGF-II binding site is at one end. (PMID:11867533)
• cDNA probes were used to analyze the gene expression of IGF type 2 receptor in luteinized granulosa cells from different-sized follicles after ovarian hyperstimulation. (PMID:12005306)
• blocks apoptosis induced by herpes simplex virus 1 mutants lacking glycoprotein D and is likely the target of antiapoptotic activity of the glycoprotein. (PMID:12021353)
• Autocrine production of IGF-I and IGF-II may via IGF-IR play a significant role in the growth and megakaryocytic differentiation of K562 cells. (PMID:12127559)
• Results suggest that M6P/IGF2R functions as a growth suppressor and its loss or mutation may contribute to development and progression of cancer. (PMID:12149131)
• Results suggest that a defect in a post-transcriptional process may exist during synthesis of the M6P/IGF2R in breast cancer cells, leading to failure to express sufficient functional M6P/IGF2R and resulting in the hypersecretion of procathepsin D. (PMID:12165733)
• 1,25(OH)(2)D(3) treatment of Caco-2 cells results in activation of latent TGF-beta 1 facilitated by the enhanced expression of IGF-II receptor (PMID:12223346)
• findings are consistent with the hypothesis that the insulin-like growth factor-II/mannose 6-phosphate receptor suppresses tumor growth (PMID:12399424)
• data suggest that the insulin-like growth factor-II- and Mannose-6-Phosphate-binding functions of the insulin-like growth factor 2 receptor have opposing activities, with respect to growth of prostate cancer cells (PMID:12586773)
• IGF-IR and IGF-IIR antisense genes could significantly restrain the malignant behavior of human hepatoma cells and might be useful in investigating a potential route for hepatocellular carcinoma gene therapy. (PMID:12603530)
• the interaction between uPAR and Man-6-P/IGF2R is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R by different mechanisms. (PMID:12665524)
• M6P/IGF2R may be involved in HBV-associated hepatocarcinogenesis by the regulation of its expression level. (PMID:12736721)
• defect in USF function may contribute to down-regulation of IGF2R expression in cancer cells. (PMID:12857727)
• neutralization of serum IGF-II by sCIMPR plays a major role in IL-6-type cytokine-dependent cell proliferation. (PMID:12959977)
• The insulin-like growth factor receptor (IGF-IR) disruption may constitute an effective tool for the control of neovascularization (PMID:14710346)
• Review delineates what is currently known about IGF-II/M6P receptor structure, its ligand binding properties and role in lysosomal enzyme transport. It also summarizes the recent data regarding the role of the receptor in the central nervous system. (PMID:15003389)
• Nay play a direct role in tumour suppression or an indirect role as a transporter for ligands designated for degradation in the lysosomes. (review) (PMID:15156403)
• Increased frequency of the cation dependent-MPR C-allele in patients with major depression, but no involvement in Alzheimer disease noted. (PMID:15167696)
• The levels of protein products of IGFR2 arwe correlated with paramateres of birth size. (PMID:15506681)
• the gly1619arg single nucleotide polymorphism of the IGF2R gene is associated with disparity in childhood stature which could reflect altered binding of IGF-II to its receptor (PMID:16172012)
• Data show that endothelial cells express CD222 and CD87 in a membrane complex and demonstrate that the association of these two receptors is essential for the release of active TGF-beta. (PMID:16179614)
• Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer (PMID:16304558)
• The ACAA-insertion/deletion polymorphism at the 3’ untranslated region of IGFIIR is associated with type 2 diabetes and influences surrogate markers of insulin resistance in non-diabetic subjects (PMID:16868148)
• CK2-activated phosphorylation cascade controlling PACS-1- and GGA3-mediated CI-MPR sorting, is reported. (PMID:16977309)
• We propose that the CIMPR luminal domain is required for tight interaction with endocytic compartments, and retention by them, and that there are additional transport steps, in which the binding to M6P-ligands is involved. (PMID:17069798)
• These observations indicate that the mammalian retromer complex assembles by sequential association of SNX1/2 and Vps26-Vps29-Vps35 subcomplexes on endosomal membranes and that SNX1 and SNX2 play interchangeable but essential roles. (PMID:17101778)
• Moreover, these M6P/IGF2R 3’UTR mutations and the TP53 mutations detected previously were mutually exclusive in most of the tumors, suggesting two independent pathways to HCC development. (PMID:17149973)
• There was a significant difference in birth weight among the three neonatal c901C>G genotypes of the insulin-like growth factor 2 receptor gene, indicating that the gene variant is associated with fetal growth. (PMID:17407457)
• novel binding surface on IGF-II critical for IGF2R binding (PMID:17475626)
• Data show that insulin-like growth factor II receptor-mediated intracellular retention of cathepsin B is essential for transformation of endothelial cells by Kaposi’s sarcoma-associated herpesvirus. (PMID:17507477)
• that endogenous IGF-1 and IGF-2 receptors can independently initiate ERK1/2 signaling and point to a potential physiologic role for IGF-2 receptors in the cellular response to IGF-2 (PMID:17620336)
• Alterations in TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 genes of microsatellite instability are rare in urinary bladder carcinoma and they are not associated with microsatellite instability or the presence of p53 mutations. (PMID:17676485)
• This pilot study of germ-line genetic variation in growth pathway genes and osteosarcoma identified a haplotype block in IGF2R associated with increased risk of osteosarcoma. (PMID:17684144)
• models reveal that the molecular interaction is driven by critical hydrophobic residues on IGF2 and IGF2R, while a ring of flexible, charged residues on IGF2R may modulate binding (PMID:17850746)
• Domain 5 of the cation-independent mannose 6-phosphate receptor preferentially binds phosphodiesters. (PMID:17927214)
• IGF2R-A2/B2 variant probably provides a selective advantage for non-small cell lung cancer progression through increased tumor growth. (PMID:18037232)
• Underlying gene defects in Fanconi Syndrome may disrupt membrane trafficking of cation-independent-mannose-6-P-receptor, leading to mistrafficking of lysosomal enzymes via a default pathway from the Golgi to the apical surface of proximal tubule cells. (PMID:18174267)
• M6P/IGF2R loss of heterozygosity predicts poor clinical outcomes in surgically resected primary hepatocellular carcinoma patients. (PMID:18322954)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	igf2r	ENSDARG00000006094
mus_musculus	Igf2r	ENSMUSG00000023830
rattus_norvegicus	Igf2r	ENSRNOG00000014997
drosophila_melanogaster	Lerp	FBGN0051072

Protein

Protein identifiers

Cation-independent mannose-6-phosphate receptor — P11717 (reviewed: P11717)

Alternative names: 300 kDa mannose 6-phosphate receptor, Insulin-like growth factor 2 receptor, Insulin-like growth factor II receptor, M6P/IGF2 receptor

All UniProt accessions (5): A0A7I2V381, A0A7I2V657, A0A7I2YQS7, P11717, S4R328

UniProt curated annotations — full annotation on UniProt →

Function. Mediates the transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex. The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation by binding DPP4.

Subunit / interactions. Binds HA-I and HA-II plasma membrane adapters. Interacts with DPP4; the interaction is direct. Binds GGA1, GGA2 and GGA3. Interacts with the heterotrimeric retromer cargo-selective complex (CSC), formed by VPS26 (VPS26A or VPS26B), VPS29 and VPS35; which is involved in retrograde trafficking of the receptor from endosomes to the Golgi apparatus. Interacts with SNX32; the interaction is involved in intracellular trafficking of the receptor.

Subcellular location. Golgi apparatus membrane. Endosome membrane.

Post-translational modifications. Palmitoylated. Undergoes cysteine S-palmitoylation which promotes interaction with the retromer cargo-selective complex which mediates its retrograde trafficking to the Golgi apparatus.

Domain organisation. Contains 15 repeating units of approximately 147 AA harboring four disulfide bonds each. The most highly conserved region within the repeat consists of a stretch of 13 AA that contains cysteines at both ends.

Similarity. Belongs to the MRL1/IGF2R family.

RefSeq proteins (1): NP_000867* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000479	CIMR_rpt	Repeat
IPR000562	FN_type2_dom	Domain
IPR009011	Man6P_isomerase_rcpt-bd_dom_sf	Homologous_superfamily
IPR013806	Kringle-like	Homologous_superfamily
IPR036943	FN_type2_sf	Homologous_superfamily
IPR044865	MRH_dom	Domain

Pfam: PF00040, PF00878

UniProt features (374 total): strand 172, disulfide bond 59, helix 29, turn 27, sequence variant 25, glycosylation site 18, domain 15, sequence conflict 15, modified residue 5, compositionally biased region 3, topological domain 2, signal peptide 1, chain 1, region of interest 1, transmembrane region 1

Structure

Experimental structures (PDB)

24 structures.

PDB	Method	Resolution (Å)
1GP0	X-RAY DIFFRACTION	1.4
6Z30	X-RAY DIFFRACTION	1.5
1E6F	X-RAY DIFFRACTION	1.75
1GQB	X-RAY DIFFRACTION	1.8
1GP3	X-RAY DIFFRACTION	1.95
1JWG	X-RAY DIFFRACTION	2
6N5X	X-RAY DIFFRACTION	2.05
6N5Y	X-RAY DIFFRACTION	2.26
1LF8	X-RAY DIFFRACTION	2.3
1JPL	X-RAY DIFFRACTION	2.4
6V02	X-RAY DIFFRACTION	2.46
6P8I	X-RAY DIFFRACTION	2.54
6Z31	X-RAY DIFFRACTION	2.56
5IEI	X-RAY DIFFRACTION	2.8
2V5O	X-RAY DIFFRACTION	2.91
2V5N	X-RAY DIFFRACTION	3.2
6Z32	X-RAY DIFFRACTION	3.47
2V5P	X-RAY DIFFRACTION	4.1
8AFZ	ELECTRON MICROSCOPY	10
2CNJ	SOLUTION NMR
2L29	SOLUTION NMR
2L2A	SOLUTION NMR
2M68	SOLUTION NMR
2M6T	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P11717-F1	73.48	0.04

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 2352, 2409, 2425, 2479, 2484

Disulfide bonds (59): 2039–2046, 2082–2113, 2096–2125, 2188–2194, 2232–2266, 2248–2278, 49–69, 77–84, 117–149, 134–161, 174–212, 228–235, 275–306, 288–318, 328–366, 374–382, 420–454, 434–466, 475–519, 531–538 …

Glycosylation sites (18): 112, 400, 435, 543, 581, 626, 747, 871, 951, 957, 1164, 1246, 1312, 1656, 1757, 1816, 2085, 2136

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-432722	Golgi Associated Vesicle Biogenesis
R-HSA-6798695	Neutrophil degranulation
R-HSA-6811440	Retrograde transport at the Trans-Golgi-Network
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828	Clathrin-mediated endocytosis
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-199991	Membrane Trafficking
R-HSA-199992	trans-Golgi Network Vesicle Budding
R-HSA-5653656	Vesicle-mediated transport
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic

MSigDB gene sets: 454 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GSE45365_NK_CELL_VS_CD8_TCELL_DN, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_LYSOSOMAL_TRANSPORT, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOCC_SECRETORY_GRANULE, GOBP_PROTEIN_TARGETING, GOCC_CELL_SURFACE, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, GOBP_VACUOLAR_TRANSPORT, KEGG_LYSOSOME, GOBP_REGENERATION, GOBP_MODULATION_OF_PROCESS_OF_ANOTHER_ORGANISM

GO Biological Process (14): liver development (GO:0001889), receptor-mediated endocytosis (GO:0006898), lysosomal transport (GO:0007041), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186), spermatogenesis (GO:0007283), post-embryonic development (GO:0009791), animal organ regeneration (GO:0031100), response to retinoic acid (GO:0032526), positive regulation of apoptotic process (GO:0043065), host-mediated activation of viral process (GO:0044794), response to tetrachloromethane (GO:1904772), regulation of apoptotic process (GO:0042981), insulin-like growth factor receptor signaling pathway (GO:0048009)

GO Molecular Function (12): G-protein alpha-subunit binding (GO:0001965), retinoic acid binding (GO:0001972), insulin-like growth factor receptor activity (GO:0005010), insulin-like growth factor binding (GO:0005520), D-mannose binding (GO:0005537), enzyme binding (GO:0019899), insulin-like growth factor II binding (GO:0031995), signaling receptor activity (GO:0038023), identical protein binding (GO:0042802), phosphoprotein binding (GO:0051219), retromer complex binding (GO:1905394), protein binding (GO:0005515)

GO Cellular Component (24): Golgi membrane (GO:0000139), nuclear envelope lumen (GO:0005641), endosome (GO:0005768), early endosome (GO:0005769), late endosome (GO:0005770), Golgi apparatus (GO:0005794), trans-Golgi network (GO:0005802), plasma membrane (GO:0005886), focal adhesion (GO:0005925), cell surface (GO:0009986), endosome membrane (GO:0010008), membrane (GO:0016020), clathrin coat (GO:0030118), transport vesicle (GO:0030133), endocytic vesicle (GO:0030139), trans-Golgi network transport vesicle (GO:0030140), secretory granule membrane (GO:0030667), clathrin-coated endocytic vesicle membrane (GO:0030669), trans-Golgi network membrane (GO:0032588), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), endomembrane system (GO:0012505)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Membrane Trafficking	3
trans-Golgi Network Vesicle Budding	1
Innate Immune System	1
Intra-Golgi and retrograde Golgi-to-ER traffic	1
Clathrin-mediated endocytosis	1
Immune System	1
Vesicle-mediated transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	4
bounding membrane of organelle	3
endomembrane system	3
cytoplasmic vesicle	3
endosome	3
cellular anatomical structure	3
apoptotic process	2
insulin-like growth factor binding	2
cytoplasm	2
cytoplasmic vesicle membrane	2
gland development	1
hepaticobiliary system development	1
endocytosis	1
vacuolar transport	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
developmental process involved in reproduction	1
male gamete generation	1
multicellular organism development	1
multicellular organismal process	1
regeneration	1
animal organ development	1
response to lipid	1
response to oxygen-containing compound	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
host-mediated perturbation of viral process	1
response to chemical	1
regulation of programmed cell death	1
cell surface receptor protein tyrosine kinase signaling pathway	1
retinoid binding	1
monocarboxylic acid binding	1
transmembrane receptor protein tyrosine kinase activity	1
insulin-like growth factor receptor signaling pathway	1
growth factor binding	1

Protein interactions and networks

STRING

2738 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IGF2R	IGF2	P01344	999
IGF2R	IGF1	P01343	995
IGF2R	INS	P01308	990
IGF2R	PLIN3	O60664	947
IGF2R	GGA1	Q9UJY5	947
IGF2R	DPP4	P27487	945
IGF2R	M6PR	P20645	916
IGF2R	SLC22A3	O75751	904
IGF2R	SLC22A2	O15244	884
IGF2R	GGA2	Q9UJY4	869
IGF2R	IGF1R	P08069	864
IGF2R	PLAU	P00749	863
IGF2R	CTSD	P07339	850
IGF2R	SNX5	Q9Y5X3	834
IGF2R	WASHC1	A8K0Z3	799

IntAct

221 interactions, top by confidence:

A	B	Type	Score
IGF2R	GGA1	psi-mi:“MI:0407”(direct interaction)	0.830
GGA1	IGF2R	psi-mi:“MI:0407”(direct interaction)	0.830
GGA1	IGF2R	psi-mi:“MI:0915”(physical association)	0.830
GGA3	IGF2R	psi-mi:“MI:0407”(direct interaction)	0.760
GGA3	IGF2R	psi-mi:“MI:0915”(physical association)	0.760
IGF2R	GGA3	psi-mi:“MI:0407”(direct interaction)	0.760
GGA3	IGF2R	psi-mi:“MI:0403”(colocalization)	0.760
HEXA	HEXB	psi-mi:“MI:0914”(association)	0.730
CTSV	CTSL	psi-mi:“MI:0914”(association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
IGF2	IGF2R	psi-mi:“MI:0407”(direct interaction)	0.560
IGF2R	IGF2	psi-mi:“MI:0407”(direct interaction)	0.560
GGA1	JUN	psi-mi:“MI:0915”(physical association)	0.540
	XPO1	psi-mi:“MI:0914”(association)	0.530

BioGRID (505): IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-Western), IGF2R (Proximity Label-MS), IGF2R (Proximity Label-MS), IGF2R (Proximity Label-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Affinity Capture-MS), IGF2R (Proximity Label-MS), IGF2R (Proximity Label-MS)

ESM2 similar proteins: A1X150, E2RK30, F1RD85, O54861, O75339, O88307, P06213, P08169, P08F94, P0DSP1, P10493, P10731, P11717, P14543, P15208, P16056, P19021, P58215, P97467, P97523, Q07113, Q07DY1, Q07DZ1, Q07E01, Q07E24, Q07E48, Q09YN5, Q108U6, Q2IBC0, Q2IBD8, Q2QL89, Q2QLA9, Q2QLH6, Q5EAB6, Q5RFQ6, Q5XIN7, Q66K08, Q6PHU5, Q75ZY9, Q8N2E2

Diamond homologs: A4KX75, D0EM77, D3ZTE0, G5EBU3, G5EGM1, O04529, O18733, O23507, O35548, O44836, O54732, O55761, O60449, O75900, O88272, O88676, O97507, P00748, P02751, P04937, P07589, P08169, P08253, P09237, P11276, P11717, P11722, P14780, P22757, P22897, P24347, P28053, P29136, P33434, P33436, P41245, P41246, P49259, P49260, P50280

SIGNOR signaling

11 interactions.

A	Effect	B	Mechanism
IGF2	up-regulates	IGF2R	binding
“LE-TGN SNARE”	“up-regulates activity”	IGF2R	relocalization
SNX5	“down-regulates quantity”	IGF2R	binding
SNX6	“down-regulates quantity”	IGF2R	binding
CSNK2A1	unknown	IGF2R	phosphorylation
PRKACA	unknown	IGF2R	phosphorylation
GZMB	up-regulates	IGF2R	binding
GCC2	“up-regulates activity”	IGF2R	relocalization
RABEPK	“up-regulates activity”	IGF2R	relocalization
PLIN3	“up-regulates activity”	IGF2R	relocalization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 222 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TBC/RABGAPs	6	11.0×	1e-03
Glycosphingolipid catabolism	5	10.4×	5e-03
NCAM signaling for neurite out-growth	5	9.6×	6e-03
Retrograde transport at the Trans-Golgi-Network	6	9.3×	3e-03
Metabolism of carbohydrates and carbohydrate derivatives	8	6.8×	2e-03
Clathrin-mediated endocytosis	10	6.0×	7e-04
Neutrophil degranulation	21	3.4×	4e-04

GO biological processes:

GO term	Partners	Fold	FDR
zinc ion transmembrane transport	7	26.0×	8e-06
intracellular zinc ion homeostasis	7	17.8×	7e-05
vesicle fusion	5	15.9×	6e-03
amino acid transport	6	9.9×	7e-03
autophagosome assembly	7	8.3×	7e-03
endocytosis	10	5.0×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

395 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	2
Uncertain significance	277
Likely benign	33
Benign	17

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
14795	NM_000876.4(IGF2R):c.4346G>T (p.Gly1449Val)	Pathogenic
14796	NM_000876.4(IGF2R):c.4391G>A (p.Gly1464Glu)	Pathogenic
915431	NM_000876.4(IGF2R):c.52_58del (p.Arg18fs)	Likely pathogenic
929753	NM_000876.4(IGF2R):c.451C>T (p.His151Tyr)	Likely pathogenic

SpliceAI

8132 predictions. Top by Δscore:

Variant	Effect	Δscore
6:159991179:TCCA:T	acceptor_loss	1.0000
6:159991181:CAG:C	acceptor_loss	1.0000
6:159991182:A:AG	acceptor_gain	1.0000
6:159991183:G:GC	acceptor_gain	1.0000
6:159991183:GT:G	acceptor_gain	1.0000
6:159991183:GTT:G	acceptor_gain	1.0000
6:159991183:GTTA:G	acceptor_gain	1.0000
6:159991183:GTTAT:G	acceptor_gain	1.0000
6:159991320:GTGG:G	donor_gain	1.0000
6:159991321:TGG:T	donor_gain	1.0000
6:159991321:TGGG:T	donor_loss	1.0000
6:159991322:GG:G	donor_gain	1.0000
6:159991322:GGG:G	donor_gain	1.0000
6:159991323:GG:G	donor_gain	1.0000
6:159991324:G:GC	donor_loss	1.0000
6:159991324:G:GG	donor_gain	1.0000
6:159991325:T:G	donor_loss	1.0000
6:160009005:A:G	acceptor_gain	1.0000
6:160009007:TAGG:T	acceptor_loss	1.0000
6:160009008:A:AG	acceptor_gain	1.0000
6:160009008:A:G	acceptor_loss	1.0000
6:160009008:AGGT:A	acceptor_gain	1.0000
6:160009009:G:A	acceptor_loss	1.0000
6:160009009:G:GA	acceptor_gain	1.0000
6:160009009:GGT:G	acceptor_gain	1.0000
6:160009009:GGTG:G	acceptor_gain	1.0000
6:160009009:GGTGA:G	acceptor_gain	1.0000
6:160009130:CCCTG:C	donor_gain	1.0000
6:160009135:G:GG	donor_gain	1.0000
6:160009136:TGAG:T	donor_loss	1.0000

AlphaMissense

16420 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:160078249:T:A	W1789R	1.000
6:160078249:T:C	W1789R	1.000
6:160078251:G:C	W1789C	1.000
6:160078251:G:T	W1789C	1.000
6:160040624:G:C	W460C	0.999
6:160040624:G:T	W460C	0.999
6:160073892:T:C	C1695R	0.999
6:160073946:T:C	C1713R	0.999
6:160084057:T:A	W1981R	0.999
6:160084057:T:C	W1981R	0.999
6:160084059:G:C	W1981C	0.999
6:160084059:G:T	W1981C	0.999
6:160089143:G:C	W2119C	0.999
6:160089143:G:T	W2119C	0.999
6:160096477:T:A	C2232S	0.999
6:160096478:G:C	C2232S	0.999
6:160096579:T:C	C2266R	0.999
6:160096597:T:A	W2272R	0.999
6:160096597:T:C	W2272R	0.999
6:160009102:A:C	S128R	0.998
6:160009104:C:A	S128R	0.998
6:160009104:C:G	S128R	0.998
6:160010735:T:A	W155R	0.998
6:160010735:T:C	W155R	0.998
6:160010737:G:C	W155C	0.998
6:160010737:G:T	W155C	0.998
6:160032602:T:A	W312R	0.998
6:160032602:T:C	W312R	0.998
6:160034465:T:A	C420S	0.998
6:160034466:G:C	C420S	0.998

dbSNP variants (sampled 300 via entrez): RS1000044342 (6:160105222 G>A), RS1000065588 (6:159996152 T>A,C,G), RS1000070590 (6:159969075 C>T), RS1000089005 (6:160067322 C>A,T), RS1000112306 (6:160085460 G>T), RS1000117601 (6:159984420 C>G), RS1000184417 (6:160086619 A>G), RS1000194151 (6:160031282 C>T), RS1000238488 (6:160019360 G>C), RS1000252903 (6:160107633 A>G), RS1000267078 (6:159985726 G>C), RS1000271595 (6:160088270 T>A,C,G), RS1000289027 (6:160052342 G>T), RS1000291379 (6:160002112 C>T), RS1000310479 (6:160012960 C>T)

Disease associations

OMIM: gene MIM:147280 | disease phenotypes: MIM:114550, MIM:130650

GenCC curated gene-disease

Mondo (5): hepatocellular carcinoma (MONDO:0007256), prostate cancer (MONDO:0008315), myoepithelial tumor (MONDO:0002380), Beckwith-Wiedemann syndrome (MONDO:0007534), primary ovarian failure (MONDO:0005387)

Orphanet (4): Hepatocellular carcinoma (Orphanet:88673), Familial prostate cancer (Orphanet:1331), Beckwith-Wiedemann syndrome (Orphanet:116), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0001402	Hepatocellular carcinoma
HP:0001413	Micronodular cirrhosis
HP:0001442	Typified by somatic mosaicism
HP:0006572	Subacute progressive viral hepatitis

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST000265_3	Brain lesion load	7.000000e-06
GCST002126_23	Periodontitis (CDC/AAP)	2.000000e-06
GCST003127_12	Lipoprotein (a) levels	5.000000e-11
GCST005196_137	Coronary artery disease	5.000000e-15
GCST005648_2	Serum metabolite concentrations in chronic kidney disease	2.000000e-18
GCST005950_13	Body mass index x sex x age interaction (4df test)	3.000000e-07
GCST005951_54	Body mass index	4.000000e-06
GCST005952_6	Body mass index (age>50)	2.000000e-08
GCST006585_1792	Blood protein levels	6.000000e-86
GCST010243_135	Apolipoprotein B levels	4.000000e-09
GCST010245_8	LDL cholesterol levels	9.000000e-10
GCST012020_568	Serum metabolite levels	1.000000e-17
GCST012020_569	Serum metabolite levels	2.000000e-11
GCST012021_16	Serum metabolite levels	1.000000e-17
GCST012021_17	Serum metabolite levels	2.000000e-11
GCST90002390_234	Mean corpuscular hemoglobin	2.000000e-10
GCST90002392_708	Mean corpuscular volume	5.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0006925	lipoprotein A measurement
EFO:0004340	body mass index
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D001506	Beckwith-Wiedemann Syndrome	C16.131.077.133; C16.131.260.080; C16.320.180.080; C16.320.447.375
D006528	Carcinoma, Hepatocellular	C04.557.470.200.025.255; C04.588.274.623.160; C06.301.623.160; C06.552.697.160
D009208	Myoepithelioma	C04.557.435.585
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3240 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs8191725	AIRN, IGF2R		0.00	0

ChEMBL bioactivities

10 potent at pChembl≥5 of 17 total, top 10 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.24	Kd	57.26	nM	CHEMBL5653589
7.24	ED50	57.26	nM	CHEMBL5653589
7.05	IC50	90	nM	CHEMBL1162089
5.75	IC50	1800	nM	CHEMBL1162088
5.50	IC50	3200	nM	CHEMBL39295
5.43	IC50	3700	nM	CHEMBL260987
5.35	IC50	4440	nM	CHEMBL448108
5.32	IC50	4760	nM	CHEMBL406598
5.30	IC50	5030	nM	CHEMBL261860
5.30	IC50	5000	nM	CHEMBL5919661

PubChem BioAssay actives

8 with measured affinity, of 22 total; 8 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148578: Binding affinity to human IGF2R incubated for 45 mins by Kinobead based pull down assay	kd	0.0573	uM
[(2R,3S,4S,5S,6R)-6-[(2S,3S,4S,5S,6R)-2-[(2R,3S)-3-acetamido-4-[[(2S)-6-[(2-aminobenzoyl)amino]-1-[[(2S,3R)-1-amino-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-oxobutan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate	318562: Displacement of pentamannosyl phosphate bovine serum albumin from M6P/IGF2R	ic50	0.0900	uM
[(2R,3S,4S,5S,6R)-6-[(2S,3S,4S,5S,6R)-2-[(2R,3S)-3-acetamido-4-[[(2S)-6-acetamido-1-[[(2S,3R)-1-amino-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-oxobutan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate	318562: Displacement of pentamannosyl phosphate bovine serum albumin from M6P/IGF2R	ic50	1.8000	uM
(Z)-3-(4-hydroxy-3-methoxyphenyl)-2-pyridin-2-ylprop-2-enenitrile	102609: Inhibition of IGF-II stimulated MCF-7 human breast tumor cell proliferation	ic50	3.2000	uM
azane;[(2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-[12-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl]oxydodecoxy]oxan-2-yl]methyl dihydrogen phosphate	318562: Displacement of pentamannosyl phosphate bovine serum albumin from M6P/IGF2R	ic50	3.7000	uM
azane;[(2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-[10-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl]oxydecoxy]oxan-2-yl]methyl dihydrogen phosphate	318562: Displacement of pentamannosyl phosphate bovine serum albumin from M6P/IGF2R	ic50	4.4400	uM
azane;[(2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-[6-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl]oxyhexoxy]oxan-2-yl]methyl dihydrogen phosphate	318562: Displacement of pentamannosyl phosphate bovine serum albumin from M6P/IGF2R	ic50	4.7600	uM
azane;[(2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-[8-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl]oxyoctoxy]oxan-2-yl]methyl dihydrogen phosphate	318562: Displacement of pentamannosyl phosphate bovine serum albumin from M6P/IGF2R	ic50	5.0300	uM

CTD chemical–gene interactions

81 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression, increases methylation	6
Valproic Acid	affects expression, increases expression	5
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
Tobacco Smoke Pollution	increases expression, affects expression, decreases expression	3
Cyclosporine	decreases expression, increases expression	3
arsenite	affects expression, affects binding, decreases reaction	2
sodium arsenite	affects expression, increases expression	2
Arsenic	affects expression, increases response to substance	2
Copper	affects binding, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	increases reaction, increases secretion, increases expression, affects binding	2
Aflatoxin B1	increases methylation	2
Cadmium Chloride	increases expression	2
FR900359	decreases phosphorylation	1
bisphenol F	increases expression	1
TL8-506	affects cotreatment, increases expression	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	increases expression	1
chloroacetaldehyde	affects expression	1
salinomycin	decreases expression	1
trichostatin A	affects expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	increases expression	1
tetrabromobisphenol A	increases expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	decreases expression, increases abundance	1
aflatoxin B2	decreases methylation	1
methacrylaldehyde	increases oxidation, affects cotreatment	1
beta-methylcholine	affects expression	1

ChEMBL screening assays

5 unique, capped per target: 4 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651620	Binding	Binding affinity to human IGF2R incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem
CHEMBL710406	Functional	Inhibition of IGF-II stimulated MCF-7 human breast tumor cell proliferation	Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents. — J Med Chem

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A2FE	SKBR-3-OE	Cancer cell line	Female
CVCL_D1WU	Abcam A-549 IGF2R KO	Cancer cell line	Male
CVCL_D2B6	Abcam HCT 116 IGF2R KO	Cancer cell line	Male
CVCL_D7RV	Ubigene A-549 IGF2R KO	Cancer cell line	Male
CVCL_SS34	HAP1 IGF2R (-) 1	Cancer cell line	Male
CVCL_XP76	HAP1 IGF2R (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00168987	PHASE4	COMPLETED	Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors
NCT00554905	PHASE4	UNKNOWN	Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
NCT00555334	PHASE4	UNKNOWN	Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00556803	PHASE4	UNKNOWN	TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
NCT00557024	PHASE4	UNKNOWN	Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00646100	PHASE4	COMPLETED	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
NCT00768157	PHASE4	UNKNOWN	Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
NCT00834860	PHASE4	UNKNOWN	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
NCT01098760	PHASE4	COMPLETED	Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
NCT01102335	PHASE4	UNKNOWN	Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
NCT01203787	PHASE4	COMPLETED	Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
NCT01298284	PHASE4	UNKNOWN	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol
NCT01332669	PHASE4	COMPLETED	Drug-eluting Bead in Hepatocellular Carcinoma
NCT01351194	PHASE4	UNKNOWN	Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm
NCT01409499	PHASE4	COMPLETED	Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT01415063	PHASE4	UNKNOWN	Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
NCT01438437	PHASE4	UNKNOWN	Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis
NCT01451658	PHASE4	UNKNOWN	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)
NCT01570075	PHASE4	UNKNOWN	Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria
NCT01575574	PHASE4	COMPLETED	Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
NCT01639703	PHASE4	COMPLETED	Hepatic Xenetix-CT Perfusion
NCT01798160	PHASE4	COMPLETED	Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
NCT01806740	PHASE4	TERMINATED	DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
NCT01849588	PHASE4	TERMINATED	HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
NCT01894269	PHASE4	UNKNOWN	Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
NCT01970748	PHASE4	UNKNOWN	Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
NCT01997957	PHASE4	UNKNOWN	A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
NCT02174575	PHASE4	WITHDRAWN	Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
NCT02253511	PHASE4	UNKNOWN	A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
NCT02399033	PHASE4	UNKNOWN	Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy
NCT02472249	PHASE4	COMPLETED	Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
NCT02504983	PHASE4	UNKNOWN	Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
NCT02525380	PHASE4	UNKNOWN	Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma
NCT02534961	PHASE4	UNKNOWN	Prophylactic Antibiotics Before RFA for HCC
NCT02535117	PHASE4	UNKNOWN	Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
NCT02729506	PHASE4	UNKNOWN	Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma
NCT02733809	PHASE4	UNKNOWN	Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
NCT02785380	PHASE4	NOT_YET_RECRUITING	Laparoscopic Surgery VS RFA for Recurrent HCC
NCT02959359	PHASE4	WITHDRAWN	DAA in the Risk of Recurrence After Curative Treatment of HCC
NCT02961998	PHASE4	COMPLETED	Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail